BLISSGVS Stock Overview
Develops, manufactures, and markets pharmaceutical formulations in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Bliss GVS Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹160.68 |
| 52 Week High | ₹179.80 |
| 52 Week Low | ₹92.15 |
| Beta | 0.84 |
| 1 Month Change | 12.32% |
| 3 Month Change | 19.63% |
| 1 Year Change | 28.90% |
| 3 Year Change | 54.95% |
| 5 Year Change | 7.69% |
| Change since IPO | 295.28% |
Recent News & Updates
Is Bliss GVS Pharma (NSE:BLISSGVS) A Risky Investment?
Dec 15
Investors Don't See Light At End Of Bliss GVS Pharma Limited's (NSE:BLISSGVS) Tunnel
Nov 23Here's Why Bliss GVS Pharma (NSE:BLISSGVS) Has Caught The Eye Of Investors
Oct 26Recent updates
Is Bliss GVS Pharma (NSE:BLISSGVS) A Risky Investment?
Dec 15Investors Don't See Light At End Of Bliss GVS Pharma Limited's (NSE:BLISSGVS) Tunnel
Nov 23Here's Why Bliss GVS Pharma (NSE:BLISSGVS) Has Caught The Eye Of Investors
Oct 26These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Safely
Aug 25Bliss GVS Pharma Limited's (NSE:BLISSGVS) Prospects Need A Boost To Lift Shares
Aug 07Increases to Bliss GVS Pharma Limited's (NSE:BLISSGVS) CEO Compensation Might Cool off for now
Jul 19Bliss GVS Pharma's (NSE:BLISSGVS) Dividend Will Be ₹0.50
Jul 18Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50
Jul 04We Think Bliss GVS Pharma's (NSE:BLISSGVS) Solid Earnings Are Understated
May 10Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Right But Growth Is Lacking
Apr 27Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Feb 20There Is A Reason Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Undemanding
Jan 26Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Jul 14Bliss GVS Pharma (NSE:BLISSGVS) Has Affirmed Its Dividend Of ₹0.50
Sep 11Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50
Aug 28These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Reasonably Well
May 21Estimating The Intrinsic Value Of Bliss GVS Pharma Limited (NSE:BLISSGVS)
Apr 08A Look At Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Returns
Mar 18Here's How We Evaluate Bliss GVS Pharma Limited's (NSE:BLISSGVS) Dividend
Feb 25Bliss GVS Pharma (NSE:BLISSGVS) Has A Pretty Healthy Balance Sheet
Feb 08What Type Of Shareholders Make Up Bliss GVS Pharma Limited's (NSE:BLISSGVS) Share Registry?
Jan 21Do Its Financials Have Any Role To Play In Driving Bliss GVS Pharma Limited's (NSE:BLISSGVS) Stock Up Recently?
Jan 08How Is Bliss GVS Pharma's (NSE:BLISSGVS) CEO Paid Relative To Peers?
Dec 26
Did Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Deserve to Gain 14%?
Dec 13Should You Use Bliss GVS Pharma's (NSE:BLISSGVS) Statutory Earnings To Analyse It?
Nov 30Shareholder Returns
| BLISSGVS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.3% | 1.7% | 0.2% |
| 1Y | 28.9% | 39.1% | 17.2% |
Return vs Industry: BLISSGVS underperformed the Indian Pharmaceuticals industry which returned 37.7% over the past year.
Return vs Market: BLISSGVS exceeded the Indian Market which returned 17.5% over the past year.
Price Volatility
| BLISSGVS volatility | |
|---|---|
| BLISSGVS Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: BLISSGVS's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: BLISSGVS's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 831 | Gagan Sharma | www.blissgvs.com |
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India and internationally. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, topical preparations, and transdermal patches. It also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, soaps, sprays, and vaginal washes.
Bliss GVS Pharma Limited Fundamentals Summary
| BLISSGVS fundamental statistics | |
|---|---|
| Market cap | ₹16.96b |
| Earnings (TTM) | ₹634.20m |
| Revenue (TTM) | ₹8.00b |
26.7x
P/E Ratio2.1x
P/S RatioIs BLISSGVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLISSGVS income statement (TTM) | |
|---|---|
| Revenue | ₹8.00b |
| Cost of Revenue | ₹4.17b |
| Gross Profit | ₹3.84b |
| Other Expenses | ₹3.20b |
| Earnings | ₹634.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.02 |
| Gross Margin | 47.94% |
| Net Profit Margin | 7.93% |
| Debt/Equity Ratio | 7.9% |
How did BLISSGVS perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield7%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 06:37 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bliss GVS Pharma Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |
| Anil Burra | FirstCall Research |